Vaxcyte, Inc. 8-K

What Happened Vaxcyte, Inc. held its Annual Meeting of Stockholders on June 15, 2026 and filed an 8‑K on June 16, 2026 reporting the vote results. Three Class III directors were re‑elected for terms running until the 2029 annual meeting: Olivier Brandicourt (For 116,370,183; Withheld 16,643,897; Broker non‑votes 4,354,403), Halley Gilbert (For 114,704,274; Withheld 18,309,806; Broker non‑votes 4,354,403), and Grant Pickering (For 132,112,840; Withheld 901,240; Broker non‑votes 4,354,403). Shareholders also ratified Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 (For 137,230,032; Against 137,589; Abstain 8,623), and approved, on a non‑binding advisory basis, the compensation of the company’s named executive officers (For 130,011,017; Against 2,755,868; Abstain 247,195; Broker non‑votes 4,354,403).

Key Details

• Annual Meeting date: June 15, 2026; 8‑K filed June 16, 2026.
• Directors re‑elected (Class III) for terms until the 2029 Annual Meeting: Olivier Brandicourt, Halley Gilbert, Grant Pickering (vote tallies above).
• Auditor ratified: Deloitte & Touche LLP approved for fiscal year ending Dec 31, 2026 (For 137,230,032).
• Non‑binding "say‑on‑pay" passed: For 130,011,017; Broker non‑votes of 4,354,403 noted on several matters.

Why It Matters These votes confirm board continuity and routine governance actions that investors watch for corporate stability and oversight. Ratification of Deloitte as auditor is a standard but important housekeeping vote that keeps the company’s audit arrangements in place. The advisory approval of executive compensation signals majority shareholder support for management pay, though it is non‑binding. The presence of broker non‑votes (4,354,403) is a factual detail showing some shares held in street name were not voted on certain matters.